Icelandic
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
lactic acid/krabbamein
Krækjan er vistuð á klemmuspjaldið
Bls 1 frá 41 niðurstöður
Lactic-acid-bacteria-containing composition, oral pharmaceutical composition for treating HPV infection and/or HPV-associated tumors, and mucosal immunity-inducing agent
Aðeins skráðir notendur geta þýtt greinar
Skráðu þig / skráðu þig
TECHNICAL FIELD
The present invention relates to a lactic acid bacterium-containing composition in which a lactic acid bacterium has a human papilloma virus (HPV) E7 protein-derived polypeptide on a surface thereof a therapeutic oral pharmaceutical composition for at least one of an HPV infectious
Local application of D-lactic acid dimer is selectively cytotoxic when applied to cancer cells
Aðeins skráðir notendur geta þýtt greinar
Skráðu þig / skráðu þig
CROSS-REFERENCES TO RELATED APPLICATIONS
None
FEDERALLY FUNDED RESEARCH
None
BACKGROUND OF THE INVENTION
Discovery of a new chemical reaction, a fundamental property of nature, is a major finding. For example, without the discovery of the Haber process, which resulted in nitrogen fixation, modern
Lactic acid bacteria and their use in the treatment of cancer
Aðeins skráðir notendur geta þýtt greinar
Skráðu þig / skráðu þig
INCORPORATION OF SEQUENCE LISTING
Two paper copies of the sequence listing (Sequence Listing No. 1 and Sequence Listing No. 2) and a computer-readable form of the sequence listing on 3.5 floppy disk containing the file named Sequence Listing.txt, as modified on Apr. 6, 2005, are herein incorporated
Use of polymer D-lactic acid (PDLA) or equivalents thereof to inhibit growth of cancer cells and diagnose cancers
Aðeins skráðir notendur geta þýtt greinar
Skráðu þig / skráðu þig
Throughout this application various publications are referenced. The disclosures of these publications in their entireties are hereby incorporated by reference into this application in order to more fully describe the state of the art to which this invention pertains.
BACKGROUND OF THE INVENTION
In
Use of polymer D-lactic acid (PDLA) or equivalents thereof to inhibit growth of cancer cells and diagnose cancers
Aðeins skráðir notendur geta þýtt greinar
Skráðu þig / skráðu þig
Throughout this application various publications are referenced. The disclosures of these publications in their entireties are hereby incorporated by reference into this application in order to more fully describe the state of the art to which this invention pertains.
BACKGROUND OF THE INVENTION
In
Compositions containing bacterium capable of converting lactic acid into butyric acid and method of preventing/treating hyperlactic acidemia in digestive tract and colon cancer by using the same
Aðeins skráðir notendur geta þýtt greinar
Skráðu þig / skráðu þig
TECHNICAL FIELD
This invention relates to a composition containing bacteria. More particularly, it relates to a composition or pharmaceutical composition for human or animals which comprises as an active ingredient bacteria or processed product thereof capable of converting lactic acid into butyric
Obligately anaerobic mutant lactic acid bacterium and preparation method therefor, and expression vector functioning in obligately anaerobic lactic acid bacterium
Aðeins skráðir notendur geta þýtt greinar
Skráðu þig / skráðu þig
FIELD OF THE INVENTION
The present invention relates to a lactic acid bacterium, useful as a therapeutic agent for a disease that is in an anaerobic environment such as a solid tumor, the lactic acid bacterium has been mutated from being facultatively anaerobic to being obligately anaerobic, a
Butyrate prodrugs derived from lactic acid
Aðeins skráðir notendur geta þýtt greinar
Skráðu þig / skráðu þig
TECHNICAL FIELD OF THE INVENTION
This invention relates to butyrate prodrugs derived from lactic acid and pharmaceutical compositions and methods employing them, either alone or in combination with other agents, for increasing gamma globin and fetal hemoglobin in a patient. These compounds,
Butyrate prodrugs derived from lactic acid
Aðeins skráðir notendur geta þýtt greinar
Skráðu þig / skráðu þig
TECHNICAL FIELD OF THE INVENTION
This invention relates to butyrate prodrugs derived from lactic acid and pharmaceutical compositions and methods employing them, either alone or in combination with other agents, for increasing gamma globin and fetal hemoglobin in a patient. These compounds,
Butyrate prodrugs derived from lactic acid
Aðeins skráðir notendur geta þýtt greinar
Skráðu þig / skráðu þig
TECHNICAL FIELD OF THE INVENTION
This invention relates to butyrate prodrugs derived from lactic acid and pharmaceutical compositions and methods employing them, either alone or in combination with other agents, for increasing gamma globin and fetal hemoglobin in a patient. These compounds,
Somatostatin analogue composition and use in treating breast cancer
Aðeins skráðir notendur geta þýtt greinar
Skráðu þig / skráðu þig
The present invention relates to a pharmaceutical composition comprising a somatostatin analogue, and to its use in the treatment of breast cancer.
Somatostatin is a tetradecapeptide incorporating a cyclic dodecapeptide having the structure: ##STR1## and has the properties of inhibiting the release
Somatostatin analogue composition and use in treating breast cancer
Aðeins skráðir notendur geta þýtt greinar
Skráðu þig / skráðu þig
The present invention relates to a pharmaceutical composition comprising a somatostatin analogue, and to its use in the treatment of breast cancer.
Somatostatin is a tetradecapeptide incorporating a cyclic dodecapeptide having the structure: ##STR1## and has the properties of inhibiting the release
Methods for inhibiting cancer growth, reducing infection and promoting general health with a fermented soy extract
Aðeins skráðir notendur geta þýtt greinar
Skráðu þig / skráðu þig
BACKGROUND OF THE INVENTION
1. Field of the Invention
This invention relates to a use or method of preventing and/or treating diseases in subjects by administering a fermented soy extract, FSE, to the subjects in need of the prevention and/or treatment of the diseases. The fermented soy extract is
Method for detecting circulating tumour cells (CTCs)
Aðeins skráðir notendur geta þýtt greinar
Skráðu þig / skráðu þig
This is the U.S. national phase of International Application No. PCT/IB2014/067057, filed Dec. 18, 2014, which designated the U.S. and claims priority to Italian Application No. RM2013A000700, filed Dec. 19, 2013; the entire contents of each of which are hereby incorporated by reference.
FIELD OF
Butyrate prodrugs derived from lactic acid
Aðeins skráðir notendur geta þýtt greinar
Skráðu þig / skráðu þig
TECHNICAL FIELD OF THE INVENTION
This invention relates to the use of butyrate prodrugs derived from lactic acid for treating inflammatory bowel disease. The invention also relates to the use of those prodrugs for the treatment of a chemotherapy-induced mucocutaneous side effect in a patient. The
Heillasta gagnagrunnur lækningajurtanna sem studdur er af vísindum
- Virkar á 55 tungumálum
- Jurtalækningar studdir af vísindum
- Jurtaviðurkenning eftir ímynd
- Gagnvirkt GPS kort - merktu jurtir á staðsetningu (kemur fljótlega)
- Lestu vísindarit sem tengjast leit þinni
- Leitaðu að lækningajurtum eftir áhrifum þeirra
- Skipuleggðu áhugamál þitt og vertu vakandi með fréttarannsóknum, klínískum rannsóknum og einkaleyfum
Sláðu inn einkenni eða sjúkdóm og lestu um jurtir sem gætu hjálpað, sláðu jurt og sjáðu sjúkdóma og einkenni sem hún er notuð við.
* Allar upplýsingar eru byggðar á birtum vísindarannsóknum
